Daniel Chamié

Daniel Chamié

Auto-generated profile, based on publicly available information

Daniel Chamié

Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
DCDaniel Chamié
Daniel Chamié
JCJ. Ribamar Costa
J. Ribamar Costa
LDLucas P. Damiani
Lucas P. Damiani
DSDimytri Siqueira
Dimytri Siqueira
SBSérgio Braga
Sérgio Braga
AAAlexandre Abizaid
Alexandre Abizaid
Background: Specific algorithms for use of optical coherence tomography (OCT) to guide percutaneous coronary intervention (PCI) are scarce. Also, the relative benefits of intravascular imaging guidance have not been tested against an optimized angiography-guided PCI strategy. In iSIGHT (Optical Coherence Tomography Versus Intravascular Ultrasound and Angiography to Guide Percutaneous Coronary Interventions), we aimed to investigate whether OCT-guided PCI achieves noninferior stent expansion compared with intravascular ultrasound (IVUS) guidance and if both imaging modalities lead to superior stent expansion compared with an optimized angiography-based strategy. Methods: Patients ≥18 years old undergoing PCI for ≥1 lesion in native coronaries of 2.25 to 4.00 mm in diameter were randomized 1:1:1 to OCT-, IVUS-, or angiography-guided PCI. Predetermined guidance protocols were applied in all groups. An external elastic membrane–based protocol was used for stent sizing by OCT and IVUS. The primary end point was noninferiority of stent expansion (minimum stent area ≥90% of the average reference lumen area), measured by post-PCI OCT, in OCT-guided versus IVUS-guided PCI (noninferiority margin, 6.5%). Results: One hundred fifty-one patients (156 lesions) were randomly allocated to OCT (51 lesions [32.7%]), IVUS (52 lesions [33.3%]), or angiography (53 lesions [34.0%]). Stent expansion with OCT guidance (98.01±16.14%) was noninferior to IVUS (91.69±15.75%; 1-sided lower 95% CI, 0.55 mm 2 ; P non-inferiority <0.001) and superior to angiography (90.53±14.84%, P =0.041). IVUS and angiography obtained similar stent expansions ( P =0.921). Stent edge dissection and periprocedural complication rates were not significantly different among the groups. Conclusions: Stent expansion with OCT guidance using a dedicated external elastic membrane–based sizing strategy was noninferior to that achieved with IVUS and superior to an optimized angiographic strategy. Registration: URL: plataformabrasil.saude.gov.br ; Unique identifier: 69968417.8.0000.5462.

16 January 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
JSJayakumar Sreenivasan
Jayakumar Sreenivasan
RRRohin Reddy
Rohin Reddy
YJYasser Jamil
Yasser Jamil
AMAaqib Malik
Aaqib Malik
DCDaniel Chamie
Daniel Chamie
YAYousif Ahmad
Yousif Ahmad
Background: Despite the initial evidence supporting the utility of intravascular imaging to guide percutaneous coronary intervention (PCI), adoption remains low. Recent new trial data have become available. An updated study‐level meta‐analysis comparing intravascular imaging to angiography to guide PCI was performed. This study aimed to evaluate the clinical outcomes of intravascular imaging–guided PCI compared with angiography‐guided PCI. Methods and Results: A random‐effects meta‐analysis was performed on the basis of the intention‐to‐treat principle. The primary outcomes were major adverse cardiac events, cardiac death, and all‐cause death. Mixed‐effects meta‐regression was performed to investigate the impact of complex PCI on the primary outcomes. A total of 16 trials with 7814 patients were included. The weighted mean follow‐up duration was 28.8 months. Intravascular imaging led to a lower risk of major adverse cardiac events (relative risk [RR], 0.67 [95% CI, 0.55–0.82]; P <0.001), cardiac death (RR, 0.49 [95% CI, 0.34–0.71]; P <0.001), stent thrombosis (RR, 0.63 [95% CI, 0.40–0.99]; P =0.046), target‐lesion revascularization (RR, 0.67 [95% CI, 0.49–0.91]; P =0.01), and target‐vessel revascularization (RR, 0.60 [95% CI, 0.45–0.80]; P <0.001). In complex lesion subsets, the point estimate for imaging‐guided PCI compared with angiography‐guided PCI for all‐cause death was a RR of 0.75 (95% CI, 0.55–1.02; P =0.07). Conclusions: In patients undergoing PCI, intravascular imaging is associated with reductions in major adverse cardiac events, cardiac death, stent thrombosis, target‐lesion revascularization, and target‐vessel revascularization. The magnitude of benefit is large and consistent across all included studies. There may also be benefits in all‐cause death, particularly in complex lesion subsets. These results support the use of intravascular imaging as standard of care and updates of clinical guidelines.


5 August 2022 in Journal of the Society for Cardiovascular Angiography & Interventions
Verified
Journal Article
Open access
GMGary S. Mintz
Gary S. Mintz
CBChristos V. Bourantas
Christos V. Bourantas
DCDaniel Chamié
Daniel Chamié
As of this writing, there have been approximately 24 randomized controlled trial publications, 32 meta-analyses, and 85 registries comparing intravascular ultrasound (IVUS) or optical coherence tomography (OCT) versus angiography-guided drug-eluting stent implantation (or IVUS versus OCT guidance). Although in specific clinical scenarios IVUS or OCT may be preferred, in most drug-eluting stent implantation procedures, either intravascular ultrasound or OCT can be used safely, efficiently, effectively, and interchangeably and will improve patient outcomes compared with stent implantation procedures performed just with angiography guidance.

5 March 2024 in Journal of the Society for Cardiovascular Angiography & Interventions
Verified
Journal Article
Open access
ZAZiad Ali
Ziad Ali
ADAntonio Dager
Antonio Dager
MZMauricio Zúñiga
Mauricio Zúñiga
JFJaime Fonseca
Jaime Fonseca
CACamilo Arana
Camilo Arana
GSGregg W. Stone
Gregg W. Stone

3 April 2020 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Open access
PDF file
AAAtul Abhyankar
Atul Abhyankar
AAAlexandre Abizaid
Alexandre Abizaid
DCDaniel Chamié
Daniel Chamié
MRMihir Rathod
Mihir Rathod
Aim: The TAXCO study was designed to compare the degree of neointimal coverage and the prevalence of malapposition at 6 months subsequent to implantation of ultrathin biodegradable polymer‐coated sirolimus‐eluting stents (SES) and durable polymer‐coated everolimus‐eluting stents (EES) of thin strut thickness using optical coherence tomography (OCT).Methods: The TAXCO study included a total of 42 patients who gave consent and underwent OCT examination between August 2017 and September 2017. Of 42, five patients' OCT examinations were of insufficient quality for quantitative analysis. Thus, the OCT analysis group consisted of 37 patients. Among them, 16 patients were treated with Xience (Abbott Vascular) and 21 with Tetriflex (Sahajanand Medical Technologies Pvt. Ltd., Surat, India), 6 (±1) months earlier at our institution. The OCT was performed using a C7 Dragonfly™ imaging catheter (St. Jude Medical Inc.). All OCT images were analyzed at an independent core laboratory (Cardiovascular Research Center, São Paulo, Brazil) by analysts who were blinded to patient and procedural information.Results: A total of 763 crosssections (6,882 struts) were analyzed in Xience group, and 1,127 crosssections (9,968 struts) in Tetriflex group. At 6 months, on per‐lesion basis, no significant differences were observed between Xience group and Tetriflex group in mean percentage of uncovered struts (1.87 ± 3.86 vs. 2.42 ± 3.46, p = .137) and malapposed struts (0.05 ± 0.2 vs. 0.21 ± 0.69, p = .302). Strut‐level neointimal thickness also did not differ between Xience group and Tetriflex group (0.18 ± 0.12 vs. 0.14 ± 0.08 mm, p = .286).Conclusion: This OCT study found no significant difference in strut coverage and neointimal thickness at 6 months after implantation of biodegradable polymer‐coated Tetriflex, when compared with durable polymer‐coated Xience.